Lista de obras - Stefano Sacchi - Dominio Público Uruguay

A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera

artículo científico publicado en 1994

A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

artículo científico publicado en 2011

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

artículo científico publicado en 2015

Activity of BKM120 and BEZ235 against Lymphoma Cells.

artículo científico publicado en 2015

Acute nonlymphocytic leukemia with trisomy 4

artículo científico publicado en 1989

Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.

artículo científico publicado en 1998

All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase

scientific article published on 01 April 1998

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

artículo científico publicado en 2005

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

artículo científico publicado en 2007

Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).

artículo científico publicado en 2002

Chromosomal abnormalities in essential thrombocythemia

Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience

artículo científico publicado en 2010

Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.

artículo científico publicado en 2004

Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines ⬇️

artículo científico publicado el 24 de mayo de 2012

Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.

artículo científico publicado en 2014

Detection of PML-RAR alpha fusion transcript in Ph positive leukemia with acute promyelocytic phenotype lacking the t(15;17) cytogenetic abnormality

artículo científico publicado en 1995

Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphyet al

scientific article published on 06 March 2014

Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia

artículo científico publicado en 2002

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

artículo científico publicado en 2010

Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects

artículo científico publicado en 1989

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease

artículo científico publicado en 2011

Future directions in haematology: beyond multiple myeloma

artículo científico publicado en 2005

Interferon alpha-2b in the long-term treatment of essential thrombocythemia

artículo científico publicado en 1991

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

artículo científico publicado en 2007

MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.

artículo científico publicado en 2006

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

artículo científico publicado en 2009

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

artículo científico publicado en 2013

Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

artículo científico publicado en 2013

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

artículo científico publicado en 2012

P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry

artículo científico publicado en 1995

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

artículo científico publicado en 2011

Persistent polyclonal B lymphocytosis: morphological, immunological, cytogenetic and molecular analysis of an Italian case.

artículo científico publicado en 2000

Platelet alpha granule release in diabetes mellitus

artículo científico publicado en 1985

Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis

scientific article published on 01 April 1986

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

artículo científico publicado en 2009

Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis

artículo científico publicado en 1993

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi

artículo científico publicado en 2013

Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

artículo científico publicado en 2011

Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

artículo científico publicado en 2011

Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.

artículo científico publicado en 2015

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

artículo científico publicado en 2007

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience

artículo científico publicado en 2005

Role of thalidomide in previously untreated patients with multiple myeloma.

scientific article published on October 2008

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

artículo científico publicado en 2016

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

artículo científico publicado en 2008

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

artículo científico publicado en 2008

Sinus histiocytosis with massive lymphadenopathy

artículo científico publicado en 1992

Sinus histiocytosis with massive lymphadenopathy: immunological, cytogenetic and molecular studies

artículo científico publicado en 1990

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.

artículo científico publicado en 2013

Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment

artículo científico publicado en 1993

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

artículo científico publicado en 2014

The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.

artículo científico publicado en 2006

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

artículo científico publicado en 2008

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

artículo científico

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update

artículo científico publicado en 1995

Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off

artículo científico publicado en 1998

Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.

artículo científico publicado en 2003

Lista de obras de Stefano Sacchi

A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera

A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Activity of BKM120 and BEZ235 against Lymphoma Cells.

Acute nonlymphocytic leukemia with trisomy 4

Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.

All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).

Chromosomal abnormalities in essential thrombocythemia

Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience

Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.

Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines ⬇️

Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.

Detection of PML-RAR alpha fusion transcript in Ph positive leukemia with acute promyelocytic phenotype lacking the t(15;17) cytogenetic abnormality

Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphyet al

Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease

Future directions in haematology: beyond multiple myeloma

Interferon alpha-2b in the long-term treatment of essential thrombocythemia

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

Persistent polyclonal B lymphocytosis: morphological, immunological, cytogenetic and molecular analysis of an Italian case.

Platelet alpha granule release in diabetes mellitus

Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi

Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience

Role of thalidomide in previously untreated patients with multiple myeloma.

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

Sinus histiocytosis with massive lymphadenopathy

Sinus histiocytosis with massive lymphadenopathy: immunological, cytogenetic and molecular studies

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.

Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update

Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off

Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.